News

Genmab holds exclusive development and commercialisation rights on 10 events out of a breast cancer database discovered using ExonHit’s genome-wide SpliceArray technology (RNA splicing analysis platform covering the

HGS said that the FDA has expressed concerns regarding the risk benefit assessment of Zalbin dosed at 900-mcg every two weeks. Although the BLA review is ongoing, HGS

Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate. In addition, no serious adverse safety events were reported for Octreolin. Chiasma said that it

Nesina, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April

Parabolic Drugs intends to add capacity at its plant in Derabassi and establish new facilities in Chachrauli and Panchkula, with a plan to use the latter for custom

According to Glucan and AGG Polycan is a clinically proved water soluble active compound which helps in maintaining good bone health and a healthy immune system. Polycan is

Patheon has posted a net income of $10.9m, compared to $0.5m for the prior year period. Operating income was $15m, compared to $13.4m for the prior year period.

According to the MMR, the patent is an asset relating to its vaccine trials and use of customized tumor cells to treat lymphoma patients. Over the past 12

The study is expected to be conducted in the Netherlands at four investigational sites and the company anticipates to evaluate total of 21 to 30 patients in the